Dyadic International Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dyadic International stock.
View analyst ratings for Dyadic International or view top-rated stocks.

1 analysts have issued 1 year price targets for Dyadic International's shares. Their DYAI stock forecasts range from $6.00 to $6.00. On average, they predict Dyadic International's share price to reach $6.00 in the next year. This suggests a possible upside of 97.4% from the stock's current price.
View analysts' price targets for Dyadic International or view top-rated stocks among Wall Street analysts.

Dyadic International's stock was trading at $4.52 on January 1st, 2022. Since then, DYAI shares have decreased by 32.7% and is now trading at $3.04.
View the best growth stocks for 2022 here.

Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Dyadic International.

Dyadic International, Inc. (NASDAQ:DYAI) announced its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $0.65 million during the quarter, compared to analyst estimates of $2.37 million. Dyadic International had a negative trailing twelve-month return on equity of 61.46% and a negative net margin of 473.45%.
View Dyadic International's earnings history.

Some companies that are related to Dyadic International include Forma Therapeutics (FMTX), Humacyte (HUMA), MeiraGTx (MGTX), Caribou Biosciences (CRBU), Mesoblast (MESO), Tarsus Pharmaceuticals (TARS), bluebird bio (BLUE), Vickers Vantage Corp. I (VCKA), DBV Technologies (DBVT), Opthea (OPT), GreenLight Biosciences (GRNA), Eiger BioPharmaceuticals (EIGR), AlloVir (ALVR), Compass Therapeutics (CMPX) and Adaptimmune Therapeutics (ADAP).
View all of DYAI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX).

Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."

Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DYAI stock can currently be purchased for approximately $3.04.

Dyadic International (NASDAQ:DYAI) has a market capitalization of $85.91 million and generates $2.40 million in revenue each year. The biotechnology company earns $-13,070,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

Dyadic International employs 7 workers across the globe.

Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The official website for Dyadic International is www.dyadic.com. The biotechnology company can be reached via phone at (561) 743-8333, via email at prawson@dyadic.com, or via fax at 561-743-8343.